NY-ESTÉE-LAUDER
18.6.2020 15:32:11 CEST | Business Wire | Press release
Today, The Estée Lauder Companies (NYSE:EL) announced that Jane Lauder will be named to the new role of Executive Vice President, Enterprise Marketing and Chief Data Officer, effective July 1, 2020. She will report directly to Fabrizio Freda, President and Chief Executive Officer, The Estée Lauder Companies (ELC). Jane will be succeeded at Clinique by Michelle Freyre, who will join the brand as Senior Vice President, General Manager, effective July 1, 2020.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200618005543/en/
As ELC’s first ever Enterprise Marketing and Chief Data Officer, Jane will lead our company-wide strategy to build our data-empowered, digitally-directed priorities to accelerate ELC’s growth. By optimizing our vast and valuable data and integrating the company’s analytic capabilities the goal is to drive breakthrough marketing and creative.
“We are focused on delivering the very best, high-quality products that leverage consumer insights from our enhanced data analytics, and I am confident that Jane is the right person to lead this important area of the business,” said Mr. Freda. “As Global Brand President of Clinique and leader of ELC’s enterprise-wide efforts to combine data-driven insights with creativity, she has successfully leveraged data and analytics capabilities to drive strong long-term growth at both the brand and enterprise level. Jane’s unique combination of understanding high-touch consumer experiences, and data analytics and insights, will further strengthen our innovative product offerings and experiences for our consumers globally. I look forward to working even more closely with Jane as she takes on this new role.”
Jane has over two decades of beauty industry experience, including more than 23 years at The Estée Lauder Companies. As Global Brand President of Clinique, she led the transformation of brand strategy, distribution, product innovation and consumer reach, positioning the brand for strong long-term growth. Under Jane’s leadership, Clinique fundamentally shifted nearly one-third of product revenue from low-growth distribution channels to high-growth channels and tripled Clinique’s online business. She also oversaw the development of product innovations including Moisture Surge™ 72-Hour Auto-Replenishing Hydrator and Clinique iD™ and technology innovations with Clinique Clinical Reality™ to strengthen the brand’s skincare position in clinical efficacy and high-touch services and personalization. Clinique’s market share gains in recent months across its core markets are a testament to the rebuilding of the brand.
Jane also leads ELC’s enterprise-wide transformation program focused on combining data and analytics capabilities with creativity to power ELC’s business and digital agenda. In her new role she will continue to drive this competency across the company. As a graduate of Stanford University and member of the Board of Directors of Eventbrite, a California-based global ticketing and event technology platform, Jane’s deep ties to Silicon Valley will be leveraged in her new role.
Jane’s organization will include BI&A, Corporate Marketing and Marketing and Consumer Supported Technology, a forward-looking portfolio management approach to data, marketing and consumer-facing technologies. ELC’s Business Insight & Analytics (BI&A) group will play a central role, and will report directly to Jane with a matrix line into Tracey T. Travis, Executive Vice President and Chief Financial Officer. Jane’s leadership will enable BI&A to continue to accelerate the Company’s ability to unlock value across brands, functions, partners and employees.
Jane will lead the global Corporate Marketing function, including the regional Corporate Marketing organizations, Consumer and Product Marketing Insights, Global Consumer Care and Marketing Planning and A&P effectiveness. She will enable the facilitation and free flow of data among business units to help these teams to mine, analyze and share strategic insights more effectively. She will also enhance the integration of cross-channel data to drive personalized marketing and true omni-channel activation.
Additionally, Jane and her team will ensure that ELC has access to cutting-edge digital innovations through a more formalized approach to strategic digital partnership management, including breakthrough marketing partnerships with leading organizations such as Facebook and Google. Her team will be scouting and developing relationships with emerging influential platforms and players in the marketing, digital innovation and consumer engagement space.
Finally, Jane will be charged with strategically deepening the company’s investments in Talent Management and Capabilities within the Marketing and Consumer Engagement teams, helping to drive talent development, recruitment and breakthrough learning and education programs, making ELC into a career destination of choice for best-in-class brand building, marketing and consumer engagement talent around the world.
About The Estée Lauder Companies Inc.
The Estée Lauder Companies Inc. is one of the world’s leading manufacturers and marketers of quality skin care, makeup, fragrance and hair care products. The company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Prescriptives, Lab Series, Origins, Tommy Hilfiger, M·A·C, Kiton, La Mer, Bobbi Brown, Donna Karan New York, DKNY, Aveda, Jo Malone London, Bumble and bumble, Michael Kors, Darphin, Tom Ford, Smashbox, Ermenegildo Zegna, AERIN, RODIN olio lusso, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, By Kilian, BECCA, Too Faced and Dr. Jart+.
ELC-C
ELC-L
View source version on businesswire.com: https://www.businesswire.com/news/home/20200618005543/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alsym Energy Announces Na-Series Battery Success Developed With Physics-Informed AI Platform27.4.2026 21:25:00 CEST | Press release
Alsym’s proprietary physics-informed AI platform powered the development of its Na-Series batteries—a non-flammable, high performance and low cost energy solution positioned to serve critical energy storage markets including data centers, utilities, telecommunications, commercial real estate, industrial and defense, among others. Alsym Energy, a pioneer in non-flammable, high-performance sodium-ion batteries, today announced details of the proprietary physics-informed AI platform used to develop the company’s recently launched Na-Series sodium-ion batteries. By integrating fundamental physics models with AI, autonomous testing and proprietary molecular diagnostics in a closed-loop system, Alsym is accelerating the design of safer, inexpensive, commercialized batteries through all phases of the development cycle. As global demand for electricity surges, the limitations of lithium-ion batteries have become increasingly apparent, particularly around safety and supply chain constraints. Li
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release
As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release
Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
